Shenzhen Neptunus Pharmaceutical Research Institute Co., Ltd.

Shenzhen Neptunus Pharmaceutical Co., Ltd.

Shenzhen Neptunus Pharmaceutical Holdings Co., Ltd.

Huawei Technologies Co., Limited

Lin Yu

Hanlin Feng

Hui Kang

Jing Wu

Tian Tang

Jinhua Zhao

Weizhen Zeng

Yong Li

Yuan Gao

Jing Li

Hong Chen

Zhiguo Wang

Zi Li

Jieke Shi

Yanqing Wang

Feng Jin

Jing'an Yang

Jing Cui

Dan Zhu

Tao Shi

Mingyi Wu

Guanghui Yao

Milai Yin

Cunfang Wang

Lijuan Zhang

Chuangui Huang

Yu Man

Hanmin Huang

Yidong Feng

Shenglin Luan

Xiarou Liu

Chien-Nan Lin

The present invention relates to a multi-target tyrosine kinase inhibitor, which is a compound having protein kinase inhibitory activity as shown in formula (I). The compound is metabolized into an active small molecule td32-4 that inhibits tumor growth in vivo, so as to achieve the anti-tumor effect. Compared with td32-4, the compound of the present invention has significantly improved solubility and oral bioavailability, and shows strong anti-tumor activity in animal in vivo experiments. The present invention relates to a synthetic method for the compound of formula (I) and an application thereof in the field of pharmaceuticals.

Multi-target tyrosine kinase inhibitor

Embossed storage tank

Provided is a composition of N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(ethoxy)-6-quinazolinyl]-4-(dimethylamino)-2-butenamide p-toluene sulfonate 1.5 hydrate &#x3b1;-polymorph. The &#x3b1;-polymorph has a stable form, a defined melting point, a good chemical stability, and a good endurance to high temperature and light irradiation, and is suitable for pharmaceutical use.

Crystal form of neptinib di-p-methylbenzenesulfonate, preparation method thereof, and pharmaceutical composition containing same

Disclosed is a depolymerized glycosaminoglycan from(dTHG), weight average molecular weight of which is about 8000&#x2dc;20000 Da, and monosaccharide components of which are acetylgalactosamine (GalNAc), glucuronic acid (GlcUA), fucose (Fuc) or their sulfates (expressed as &#x2014;OSO), in which molar ratio of GalNAc:GlcUA:Fuc:&#x2014;OSOis about 1:(1&#xb1;0.3):(1&#xb1;0.3):(3.5&#xb1;0.5). Said dTHG is a potent endogenous inhibitor of factor X, which has good anticoagulant and antithrombotic activity, and can be used for the prevention and/or treatment of thrombotic diseases. Also provided is a method for preparing said dTHG, which comprises steps of 1) extracting and obtaining fucosylated glycosaminoglycan (THG) from the body wall of; 2) depolymerizing THG to obtain dTHG by method of peroxide depolymerization or method of peroxide depolymerization catalyzed by catalyst of the fourth period transition metal ions; 3) removing impurities with lower and/or higher molecular weight in dTHG.

[object Object]

The present invention relates to a novel crystalline form of a Compound 3,4',5-trihydroxy-stilbene-3-&#x3b2;-D-glucoside (polydatin) and a method of preparation and use thereof, and to a pharmaceutical composition containing crystalline form I of 3,4&#x2032;,5-trihydroxy-stilbene-3-&#x3b2;-D-glucoside. Crystalline form I of 3,4&#x2032;,5-trihydroxy-stilbene-3-&#x3b2;-D-glucoside of the present invention has a stable crystalline morphology, a definite melting point and a good chemical stability. Such a novel form of 3,4&#x2032;,5-trihydroxy-stilbene-3-&#x3b2;-D-glucoside possesses the properties required for the preparation of solid formulations and is easily tabletable and readily formable when formulated, which allows for substantial decrease in raw materials costs, more facile operations in production and easier control over quality in industrial drug production, and moreover, better convenience in storage.

Crystalline form I of 3,4'5-trihydroxy-stilbene-3-&#x3b2;-D glucoside

Growing community of inventors

Shenzhen, China

Lin Yu